Who is sponsoring NCT06778317?

NCT06778317 is sponsored by Central Hospital, Nancy, France.

What drugs are being tested in NCT06778317?

Interventions in NCT06778317: Circulating mSEPT9 Biomarker Testing.

What condition does NCT06778317 study?

NCT06778317 studies Hepatocellular Carcinoma (HCC), Cirrhosis, Risk Prediction for Liver Cancer, Epigenomics.

Is NCT06778317 still recruiting?

NCT06778317 is currently not yet recruiting. Last updated 20 January 2025.

Last reviewed 2025-01-20 · How we verify

NCT06778317: SEPT9_SuRV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients with Cirrhosis

Not yet recruiting Last updated 20 January 2025

What this trial tests

trial testing Circulating mSEPT9 Biomarker Testing in Hepatocellular Carcinoma (HCC) in 400 participants. Not yet recruiting.

Timeline

3 March 2025

Primary endpoint
4 March 2030

3 March 2031

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	400
Start date	3 March 2025
Primary completion	4 March 2030
Estimated completion	3 March 2031
Sites	1 location across France

Drugs / interventions tested

Circulating mSEPT9 Biomarker Testing

Conditions studied

Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →
Cirrhosis — all drugs for Cirrhosis →
Risk Prediction for Liver Cancer — all drugs for Risk Prediction for Liver Cancer →
Epigenomics — all drugs for Epigenomics →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Hepatocellular Carcinoma (HCC) or Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the role of the circulating epigenetic biomarker mSEPT9 in predicting the risk of hepatocellular carcinoma (HCC) in patients with cirrhosis. HCC is a primary liver cancer that frequently develops in individuals with cirrhosis, and early detection is critical for improving outcomes. This research involves 400 patients with cirrhosis who will be followed every six months for up to 60 months. During these visits, blood samples will be collected to analyze mSEPT9 levels. By identifying changes in this biomarker, the study seeks to improve early diagnosis and personalize surveillance strategies, potentially enhancing patient survival and quality of life.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies.
Anees M, Sherry C, Park HY, Grayhack EE, et al · · 2026 · PMID 41866828 · DOI 10.1002/ctm2.70594

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07070076 — A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther · NA · recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07490262 — A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular · Phase 2, PHASE3 · recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06778317 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 20 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06778317.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing